David Bailey Acquires 4,852 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,852 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were purchased at an average price of $6.27 per share, for a total transaction of $30,422.04. Following the transaction, the chief executive officer directly owned 3,185,246 shares of the company’s stock, valued at approximately $19,971,492.42. This represents a 0.15% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

KindlyMD Stock Performance

KindlyMD stock opened at $7.06 on Friday. KindlyMD, Inc. has a fifty-two week low of $3.33 and a fifty-two week high of $422.40. The company has a market capitalization of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95. The stock has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $7.24.

KindlyMD (NASDAQ:NAKA) last announced its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. The firm had revenue of $35.87 million during the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. As a group, analysts forecast that KindlyMD, Inc. will post -11.31 earnings per share for the current year.

Institutional Trading of KindlyMD

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. J. Derek Lewis & Associates Inc. acquired a new stake in KindlyMD during the 4th quarter worth approximately $167,000. Virtu Financial LLC acquired a new position in shares of KindlyMD in the fourth quarter valued at approximately $151,000. Invesco Ltd. acquired a new position in shares of KindlyMD in the fourth quarter valued at approximately $211,000. NewEdge Advisors LLC purchased a new stake in shares of KindlyMD during the fourth quarter worth approximately $316,000. Finally, Saba Capital Management L.P. purchased a new stake in shares of KindlyMD during the fourth quarter worth approximately $1,399,000.

Key Headlines Impacting KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NAKA. Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. TD Cowen upped their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $22.33.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.